Trading Halt
Filed with ASX · · 2 pages · English
On 6ix: 6ix.com/news/trading-halt-684
Trading in the securities of Neuroscientific Biopharmaceuticals Ltd (‘NSB’) will be halted at the request of NSB, pending the release of an announcement by NSB. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Tuesday, 13 January 2026; or • the release of the announcement to the market. NSB’s request for a tradin
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Fourth Patient Commences StemSmart MSC Treatment
- 2025 Annual Report & Appendix 4E
- Previous StemSmart Studies Support Renal Transplantation
- Experienced Cell Therapy Executive Appointed CEO
- StemSmart Acquisition Complete
Later from Neuroscientific Biopharmaceuticals
- Successful Clinical Results Achieved under Special Access
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Remarkable Results from Patients treated with StemSmart
- 2026 Annual Report & Appendix 4E
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals